Manufacturer
ROCHE DIAGNOSTICS GMBH
Contents
Trastuzumab
Indication
Metastatic breast cancer (MBC) tumors that overexpress human epidermal growth factor receptor 2 (HER2): Monotherapy for patients who have received ≥1 chemotherapy regimens; in combination w/ paclitaxel or docetaxel for patients who have not received chemotherapy; in combination w/ aromatase inhibitor for patients w/ hormone-receptor positive MBC. HER2 positive early breast cancer (EBC): Following surgery, neoadjuvant or adjuvant chemotherapy & radiotherapy (if applicable); following adjuvant chemotherapy w/ doxorubicin & cyclophosphamide, in combination w/ paclitaxel or docetaxel; in combination w/ adjuvant chemotherapy consisting of docetaxel & carboplatin; in combination w/ neoadjuvant chemotherapy followed by adjuvant Herceptin, for locally advanced (including inflammatory) breast cancer or tumours >2 cm in diameter. IV: In combination w/ capecitabine or 5-fluorouracil & cisplatin for patients w/ HER2 positive metastatic stomach or gastroesophageal junction adenocarcinoma who have not received prior anti-cancer treatment.
Instruction
IV MBC & EBC Wkly schedule: Initial loading dose: 4 mg/kg as 90-min IV infusion, subsequently 2 mg/kg wkly as 30-min infusion. Alternative 3-wkly schedule: Initial loading dose: 8 mg/kg, followed by 6 mg/kg 3 wk later & then 6 mg/kg repeated at 3-wkly intervals as infusion over approx 90 min. If well tolerated, may be administered as 30-min infusion. Metastatic gastric cancer 3-wkly schedule: Initial loading dose: 8 mg/kg followed by 6 mg/kg 3 wk later & then 6 mg/kg repeated at 3-wkly intervals as infusion over approx 90 min. If well tolerated, may be administered as 30 min-infusion. SC MBC & EBC 600 mg fixed dose every 3 wk.
Drug interaction
Elevated overall exposure of doxorubicin metabolite (7-deoxy-13 dihydro-doxorubicinone). Higher conc & longer t½ of capecitabine.
Malaysia
